A detailed history of Wealthfront Advisers LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Wealthfront Advisers LLC holds 5,500 shares of EXAS stock, worth $291,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,500
Previous 5,589 1.59%
Holding current value
$291,005
Previous $236,000 58.47%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$42.43 - $70.83 $3,776 - $6,303
-89 Reduced 1.59%
5,500 $374,000
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $90,719 - $163,000
-2,195 Reduced 28.2%
5,589 $236,000
Q1 2024

Apr 19, 2024

SELL
$56.27 - $73.77 $9,678 - $12,688
-172 Reduced 2.16%
7,784 $537,000
Q4 2023

Feb 09, 2024

SELL
$59.06 - $75.72 $6,142 - $7,874
-104 Reduced 1.29%
7,956 $588,000
Q3 2023

Nov 01, 2023

SELL
$65.94 - $99.04 $12,924 - $19,411
-196 Reduced 2.37%
8,060 $549,000
Q2 2023

Aug 07, 2023

SELL
$62.68 - $95.05 $8,524 - $12,926
-136 Reduced 1.62%
8,256 $775,000
Q1 2023

Apr 28, 2023

SELL
$47.19 - $70.77 $15,714 - $23,566
-333 Reduced 3.82%
8,392 $569,000
Q4 2022

Feb 10, 2023

BUY
$30.35 - $53.15 $264,803 - $463,733
8,725 New
8,725 $431,000
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $353,706 - $507,208
-6,145 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$72.5 - $100.68 $300,150 - $416,815
-4,140 Reduced 40.25%
6,145 $478,000
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $928,118 - $1.28 Million
10,285 New
10,285 $982,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.36B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Wealthfront Advisers LLC Portfolio

Follow Wealthfront Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthfront Advisers LLC with notifications on news.